Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.
Ekström N, Ahman H, Palmu A, Grönholm S, Kilpi T, Käyhty H; FinOM Study Group. Ekström N, et al. Among authors: ahman h. Clin Vaccine Immunol. 2013 Jul;20(7):1034-40. doi: 10.1128/CVI.00039-13. Epub 2013 May 8. Clin Vaccine Immunol. 2013. PMID: 23658394 Free PMC article. Clinical Trial.
Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age.
Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Käyhty H, et al. Among authors: ahman h. Pediatr Infect Dis J. 2005 Feb;24(2):108-14. doi: 10.1097/01.inf.0000151022.92222.be. Pediatr Infect Dis J. 2005. PMID: 15702037 Clinical Trial.
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.
Ekström N, Ahman H, Verho J, Jokinen J, Väkeväinen M, Kilpi T, Käyhty H. Ekström N, et al. Among authors: ahman h. Infect Immun. 2005 Jan;73(1):369-77. doi: 10.1128/IAI.73.1.369-377.2005. Infect Immun. 2005. PMID: 15618174 Free PMC article. Clinical Trial.
Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media.
Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty MH. Jokinen JT, et al. J Infect Dis. 2004 Aug 1;190(3):545-50. doi: 10.1086/422531. Epub 2004 Jul 2. J Infect Dis. 2004. PMID: 15243930 Clinical Trial.
Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, Käyhty H, Bohidar N, Sadoff JC, Mäkelä PH; Finnish Otitis Media Study Group. Kilpi T, et al. Clin Infect Dis. 2003 Nov 1;37(9):1155-64. doi: 10.1086/378744. Epub 2003 Oct 7. Clin Infect Dis. 2003. PMID: 14557958 Clinical Trial.
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
Ahman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Ahman H, et al. Pediatr Infect Dis J. 1996 Feb;15(2):134-9. doi: 10.1097/00006454-199602000-00009. Pediatr Infect Dis J. 1996. PMID: 8822286
The infants received simultaneously H. influenzae type b oligosaccharide-CRM197 conjugate vaccine. Serum samples were taken before each dose and 1 month after the third dose. ...Enzyme-linked immunosorbent assay was used to measure serum IgG anti-pneumococcal polysaccharid …
The infants received simultaneously H. influenzae type b oligosaccharide-CRM197 conjugate vaccine. Serum samples were taken before ea …
Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.
Käyhty H, Ahman H, Rönnberg PR, Tillikainen R, Eskola J. Käyhty H, et al. J Infect Dis. 1995 Nov;172(5):1273-8. doi: 10.1093/infdis/172.5.1273. J Infect Dis. 1995. PMID: 7594664 Clinical Trial.
Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.
Nurkka A, Ahman H, Korkeila M, Jäntti V, Käyhty H, Eskola J. Nurkka A, et al. Pediatr Infect Dis J. 2001 Jan;20(1):25-33. doi: 10.1097/00006454-200101000-00006. Pediatr Infect Dis J. 2001. PMID: 11176563
25 results
Jump to page
Feedback